Objective: The objectives of this study are to determine immunization rates at discharge from the neonatal intensive care unit (NICU) among infants 2 months of age and above and to evaluate risk factors for underimmunization.
Introduction
Infants in the neonatal intensive care unit (NICU) are at risk for future underimmunization. Low birth weight (less than 2500 g) children have been shown to have increased rates of underimmunization at both 24 1 and 36 months 2 of age. Other studies have found that lower gestational age is also associated with decreased immunization rates. 3 Infants in the NICU are at particularly high risk of delayed immunization. A study of infants discharged from the special care nursery found that >50% of all infants were not up-to-date on immunizations at 6 months of age. In very low birth weight infants in the same cohort, underimmunization (not up-to-date) rates were >90%. 4 Davis et al. 5 demonstrated that infants who spent time in the NICU were less likely to be fully vaccinated at 12 and 24 months of age than their age-matched peers.
Studies of immunization rates in infants discharged from the NICU (preterm and low birth weight infants) are often conducted in children of 1 year or older. By this age, most children who spent time in the NICU have been discharged and are cared for by primary health care providers. A subset of preterm and low birth weight infants, however, remains in the NICU beyond 2 months of age, when they become eligible to receive routine childhood immunizations other than hepatitis B vaccine. Immunization rates in this subset of infants have not been studied. High rates of immunization are theoretically attainable in the NICU, where all infants have access to healthcare, but may be limited by lack of provider knowledge about vaccine recommendations or concerns about potential adverse events. Because immunization delay in infancy contributes to underimmunization at later ages, it is important to identify when the delay begins.
1,2,4,5 We evaluated immunization rates in a cohort of infants who remained in the NICU beyond 2 months to determine immunization rates in infants 60 days of age or older, as they are discharged from the NICU.
Methods
We recently reported the results of a retrospective cohort study of infants in all six level-three NICUs in the Northern California Kaiser Permanente Medical Care Program (KPMCP). 6 The goal of that previous study was to evaluate apnea, following routine immunizations in infants in the NICU. Using this same cohort, this study sought to evaluate immunization rates of children upon discharge from the NICU.
To capture infants eligible for the 2-month vaccine series, all infants born from 1 January 1997 through 31 December 2003 who were in the NICU at least 60 days were eligible for inclusion. Starting in 1997, discharge information for infants in the NICU included an indicator for whether or not the child received a vaccine while in the NICU. Medical record analysts reviewed the charts for all infants who received at least one vaccine on or after the age of 60 days in the NICU, and captured data on all vaccines administered in the NICU. Vaccinated infants on whom chart data were not available were excluded. The current study was approved by the institutional review boards at Northern California KPMCP, Duke University Medical Center and Johns Hopkins University School of Public Health.
KPMCP maintains an ongoing automated database that tracks all NICU admissions. 7 Data on admission and discharge dates, birth dates, birth weight, gestational age, Apgar scores at 1 and 5 min, ICD-9 (International Classification of Diseases, version 9) codes for all diagnoses made and procedures performed, and SNAP-II (Score for Neonatal Acute Physiology, version 2) scores were obtained from this database for all eligible infants. ICD-9 diagnoses codes reflect all diagnoses and procedures performed on the infant throughout their stay in the NICU. The SNAP-II score is a composite score measured 12 h after admission to the NICU and is a validated predictor of risk of death in the NICU. Higher scores indicate worse prognosis. 8, 9 Procedure codes were reviewed to determine which children underwent abdominal, thoracic or neurologic surgery before discharge.
Statistical analysis
Vaccines recommended for use in the NICU throughout the study period for 2, 4 and 6-month immunization series were polio vaccine (oral-OPV or inactivated-IPV), diphtheria toxoid, tetanus toxoid and pertussis (whole cell-(diphtheria, tetanus and whole-cell pertussis vaccine) DTP or acellular-diphtheria, tetanus and acellular pertussis vaccine (DTaP)) vaccine, hepatitis B vaccine (Hep B) and Haemophilus influenzae type b conjugate vaccine (Hib). Table 1 indicates the number of doses of each vaccine required for a child to be considered 'up-to-date' by age at discharge.
The percent of children not up-to-date at discharge was calculated on the basis of requirements delineated in Table 1 . Vaccine-specific immunization rates were also calculated. A w 2 -test using three degrees of freedom was used to test for a difference in at least one of the antigen-specific immunization rates. Characteristics of children up-to-date and children not up-to-date at discharge were compared using bivariate logistic regression. Characteristics evaluated included birth weight, gestational age, Apgar scores, SNAP-II scores, percent having requiring mechanical ventilation at any time in the NICU, percent small for gestational age, discharge age, as well as presence or absence of pulmonary disease, congenital heart disease, apnea and bronchopulmonary dysplasia. Multivariate logistic regression for the odds of becoming up-to-date was performed including all variables significant at the P<0.05 level in bivariate analyses. All data analyses were performed using STATA 8.0 (Stata, College Station, TX, USA).
Results

Study population
Seven hundred and twelve infants were discharged on or after age 60 days from the NICU. Five hundred and twenty infants (73%) received at least one vaccine. Chart review data were available on 498 of the 520 infants (95% of vaccinated infants). 1 One child was excluded by investigators at KPMCP due to a severe congenital anomaly. One hundred and ninety-two infants discharged on or after 60 days of age received no vaccines (27%). Data were unavailable for one unimmunized child. A total of 688 infants (191 unimmunized and 497 immunized) discharged on or after 60 days of age were included in the analyses.
Vaccination status at discharge
Of 688 children in the NICU discharged on or after 60 days of age, 51% were up-to-date with immunizations at the time of discharge. Table 2 shows the percent of children up-to-date for each vaccine recommended. Just over half (50.7%) of infants were up-to-date at discharge for DTaP/DTP, HepB, HiB and IPV/OPV. No difference was seen in immunization rates by specific vaccine type (P-value for difference ¼ 0.18). Table 3 shows the characteristics of children who were up-todate at discharge compared with children who were not up-to-date at discharge. Children who were up-to-date at discharge had lower gestational ages, higher rates of mechanical ventilation, higher rates of apnea, higher rates of bronchopulmonary dysplasia and congenital heart disease, and lower rates of surgery than children not up-to-date at discharge in univariate analysis. No difference was seen in Apgar scores, birth weight, SNAP-II sores, percent small for gestational age or length of stay between infants up-to-date at discharge and infants not up-to-date at discharge. In multivariate logistic regression, having undergone surgery significantly decreased the likelihood of being up-to-date, whereas a diagnoses of apnea, congenital heart disease and bronchopulmonary dysplasia significantly increased the likelihood of being up-to-date for DTP, HepB, Hib and polio at discharge. Of the 339 infants not up-to-date at discharge, 148 children received at least one vaccine on or after age 60 days. On many occasions, infants received some, but not all, vaccines recommended for administration at that time. If all recommended vaccines had been given at the time of immunization, the percent of children up-to-date at discharge would have been increased from 50.7 to 66.4%.
Children who received no vaccines At discharge, 192 children, or 27.0%, of all 712 children discharged from the NICU on or after 60 days of age, had received zero vaccines. Characteristics of children who received no vaccines were similar to characteristics of children not up-to-date at discharge (analysis not shown).
Discussion
Despite having access to healthcare and universal insurance, roughly half of the infants discharged from the NICU in this cohort were up-to-date on immunizations. Additionally, only 20.8% of infants discharged between the age of 4 and 6 months were up-todate for routine immunizations. These outcomes are consistent with a number of older studies demonstrating that low birth weight and prematurity are risk factors for underimmunization. However, this is the first study to document underimmunization in children as they are discharged from the NICU. Less than 5% of all NICU admissions at KPMCP during the study period resulted in a length of stay of 60 days or more; thus, most infants were discharged before reaching the age for receipt of 2-month vaccines. Therefore, underimmunization beginning in the NICU only explains a small portion of underimmunization seen in preterm and low birth weight infants.
Underimmunized infants consist of those who received some, but not all, recommended vaccines, as well as infants who received no vaccines. Ensuring that infants who are vaccinated receive all recommended vaccines before discharge should help improve immunization rates. Providers may have not administered all appropriate vaccines at the recommended immunization time because of lack of knowledge of the immunization schedule at the time, a preference for administrating fewer vaccines at the same Abbreviations: DtaP, diphtheria, tetanus and acellular pertussis vaccine; DTP, diphtheria, tetanus and whole-cell pertussis vaccine; HepB, hepatitis B vaccine; Hib, Haemophilus influenzae type b conjugate vaccine; IPV, inactivated polio vaccine; OPV, oral polio vaccine. *See Table 1 for the # of vaccine doses required by age at discharge for a child to be considered 'up-to-date'. and 13% developed apnea following immunizations. 6 Another potential barrier to immunization in the NICU is obtaining consent of parents, which is difficult given that many parents are not continuously present in the NICU. Efforts to discuss immunizations early in the hospitalization (instead of immediately before discharge) may help providers to more easily obtain consent from parents. Barriers to immunization in the NICU should be further explored, including provider and parental attitudes towards immunizations.
A limitation to our analysis is our inclusion of infants in six NICUs within the same health system. Whether or not similar rates of immunization occur in other healthcare systems remains unknown. It is possible that immunization rates in the NICU are lower in this managed care setting, as it is a fully integrated system with very close discharge follow-up for infants discharged from the NICU. Providers in this system may not prioritize immunization in infants who will be seen by their primary care provider soon after discharge. However, waiting to vaccinate until primary care follow-up only furthers immunization delay.
Chart review data were used to confirm vaccines administered. As a result, vaccinated infants without available chart review data were excluded from analysis. However, unvaccinated children were not excluded, as chart review data were not necessary for unvaccinated children. All characteristics analyzed for unvaccinated children were obtained from automated databases. However, the 22 vaccinated infants who were excluded represented only 3% of the initial population and would have had only a minimal effect on the immunization rate in this analysis.
These data reflect immunization status of infants born between 1997 and 2003. Since that time, institutional policy has not changed regarding immunizations of neonates at discharge. All six NICUs in the KMPCP system follow the AAP guidelines for immunization of preterm and low birthweight infants, which have been reinforced, but not substantially altered since the study was performed. 11 Since 1997, the AAP has recommended immunization of preterm and low birthweight infants, according to chronological age with two exceptions: 1) changes have been made over time regarding timing of the birth dose of hepatitis B vaccine and 2) the AAP added pneumococcal conjugate vaccine as a recommended immunization. Therefore, it is unlikely that the rate of underimmunization in infants leaving the NICU has diminished over time in response to changes in institutional or AAP guidelines. However, changes in other institutions' policies over time are unknown. One survey of 30 NICUs across the United States found that whereas 83% had a policy on immunization, only 27% of those had a policy that followed the AAP recommendation for age at of administration. Additionally, only three NICUs enforced their immunization guidelines. 4 We have not identified more recent data to determine if this trend has changed nationwide.
A surprising finding was that infants who received no vaccines tended to be healthier than infants who were vaccinated for the variables we assessed, with higher average birth weights and gestational ages, lower rates of mechanical ventilation, and lower rates of cardiac and pulmonary disease. Infants with poorer prognostic indicators may have higher immunization rates, because they require more clinical attention overall.
Infants who underwent abdominal, thoracic or neurologic surgery were more likely to be unimmunized or underimmunized, possibly because of multiple providers caring for a single infant, or concerns about the effects of immunization delaying surgery or confounding post-operative assessments. Provider attention may be more focused on the surgical disease rather than other preventive measures. Infants diagnosed with apnea at some point during their NICU stay and those with bronchopulmonary dysplasia had higher rates of immunization than infants without either. The diagnosis of apnea could be made before or after immunization, so the higher rate of apnea in immunized infants could reflect increased immunization of infants with apnea or the development of postimmunization apnea in immunized infants. Alternatively, providers may have been more vigilant about all preventive measures, including vaccines, in infants with pulmonary disease.
Underimmunized infants who are discharged from the NICU to their outpatient provider should start on a catch-up schedule. This can be burdensome for providers and parents, as it requires closer spacing of visits and additional knowledge about the vaccine schedule. Many pediatricians and family physicians are unfamiliar with guidelines for immunization of preterm and low birth weight infants. 12, 13 Initiation of on-time immunization for these infants while in the NICU can help reassure providers of the safety of immunization.
In summary, we found that many infants discharged out of the NICU on or after age 60 days were not fully protected against vaccine preventable diseases. Children in the NICU at KPMCP are all in regular contact with the healthcare system and are universally insured, so high immunization rates should be attainable. Lower rates of immunization leave these children at increased risk for contracting vaccine preventable diseases. Performance initiatives should consider evaluation of immunization status of infants at discharge as a potential target for quality assessment and ongoing improvement.
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